Found: 15
Select item for more details and to access through your institution.
Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry.
- Published in:
- Clinical Breast Cancer, 2024, v. 24, n. 2, p. 103, doi. 10.1016/j.clbc.2023.10.009
- By:
- Publication type:
- Article
Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry.
- Published in:
- Breast Cancer Research & Treatment, 2024, v. 205, n. 2, p. 287, doi. 10.1007/s10549-023-07235-0
- By:
- Publication type:
- Article
The prognostic impact of BMI in patients with HR+/HER2− advanced breast cancer: a study of the SONABRE registry.
- Published in:
- Breast Cancer Research & Treatment, 2024, v. 203, n. 2, p. 339, doi. 10.1007/s10549-023-07108-6
- By:
- Publication type:
- Article
Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry.
- Published in:
- Breast Cancer Research & Treatment, 2023, v. 198, n. 2, p. 239, doi. 10.1007/s10549-022-06832-9
- By:
- Publication type:
- Article
The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 192, n. 2, p. 331, doi. 10.1007/s10549-021-06472-5
- By:
- Publication type:
- Article
Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 188, n. 2, p. 571, doi. 10.1007/s10549-021-06178-8
- By:
- Publication type:
- Article
Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial.
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 185, n. 3, p. 741, doi. 10.1007/s10549-020-05991-x
- By:
- Publication type:
- Article
Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study.
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 185, n. 2, p. 441, doi. 10.1007/s10549-020-05966-y
- By:
- Publication type:
- Article
Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I-IIIB breast cancer receiving chemotherapy.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 173, n. 2, p. 475, doi. 10.1007/s10549-018-5014-5
- By:
- Publication type:
- Article
Development of a Clinical Prediction Model for 1-Year Mortality in Patients With Advanced Cancer.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 11, p. e2244350, doi. 10.1001/jamanetworkopen.2022.44350
- By:
- Publication type:
- Article
Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
- Published in:
- 2019
- By:
- Publication type:
- journal article
Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
- Published in:
- 2016
- By:
- Publication type:
- journal article
Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2008, v. 62, n. 5, p. 841, doi. 10.1007/s00280-007-0671-9
- By:
- Publication type:
- Article
A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00563-w
- By:
- Publication type:
- Article